Related Experiment Videos
Ret-proto-oncogene analysis in medullary thyroid carcinoma
D A O'Keeffe1, A D Hill, K Sheahan
1Department of Surgery, University College Dublin.
Irish Journal of Medical Science
|December 30, 1998
Summary
RET proto-oncogene mutation analysis reliably distinguishes familial from sporadic medullary thyroid carcinoma (MTC). This testing identifies at-risk family members, enabling proactive clinical management for hereditary MTC.
Area of Science:
- Oncology
- Genetics
- Endocrinology
Background:
- Medullary thyroid carcinoma (MTC) presents as sporadic or hereditary forms.
- RET proto-oncogene mutations are linked to hereditary MTC.
- Identifying familial MTC is crucial for genetic counseling and management.
Purpose of the Study:
- To investigate RET proto-oncogene germline mutations in MTC patients.
- To differentiate between sporadic and hereditary forms of MTC.
- To assess familial risk and guide clinical decisions.
Main Methods:
- Analysis of RET proto-oncogene germline mutations in nine MTC patients and four children.
- Utilized peripheral blood or archival thyroid tissue for DNA analysis.
- Sequencing of RET proto-oncogene exons 10 and 16.
Main Results:
- Seven patients had sporadic MTC confirmed by RET mutational analysis.
- Three of four at-risk children inherited the RET codon 618 mutation from their fathers.
- One patient diagnosed with MEN2B confirmed by RET exon 16 mutation; two children showed C-cell hyperplasia post-prophylactic thyroidectomy.
Conclusions:
- RET proto-oncogene analysis is a definitive method for distinguishing familial from sporadic MTC.
- Germline mutation status in RET guides risk assessment for family members.
- Mutational findings enable targeted clinical management and prophylactic interventions.